Literature DB >> 20941603

Phenotypic and functional characterization of CD8(+) T regulatory cells.

Séverine Ménoret1, Carole Guillonneau, Séverine Bezié, Lise Caron, Ignacio Anegon, Xian-Liang Li.   

Abstract

Increasing evidence shows the presence and significance of CD8+ T regulatory cells (CD8+ Tregs) in both human and rodent transplant recipients, as well as in autoimmune disease models. We, hereafter, review all available data on the phenotypic and functional characterization of CD8+ Tregs, and we also provide detailed protocols to purify them and analyze their suppressive function. Different subsets of dendritic cells (DCs) and CD4+ effector T cells may modulate the suppression mediated by CD8+ Tregs. By analyzing the proliferation of CFSE-labeled naïve CD4+CD25- T cells in coculture MLR and transwell experiments, we explored the mutual modulation of CD8+ Tregs, DC subsets, and CD4+ T effector cells. The suppressive function of CD8+ Tregs was mediated by both cell-contact-dependent and -independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20941603     DOI: 10.1007/978-1-60761-869-0_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  Oligoclonal CD8+ T cells play a critical role in the development of hypertension.

Authors:  Daniel W Trott; Salim R Thabet; Annet Kirabo; Mohamed A Saleh; Hana Itani; Allison E Norlander; Jing Wu; Anna Goldstein; William J Arendshorst; Meena S Madhur; Wei Chen; Chung-I Li; Yu Shyr; David G Harrison
Journal:  Hypertension       Date:  2014-08-04       Impact factor: 10.190

2.  In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients.

Authors:  Séverine Bézie; Claire Usal; Carole Guillonneau
Journal:  J Vis Exp       Date:  2017-08-12       Impact factor: 1.355

3.  IL-34 is a Treg-specific cytokine and mediates transplant tolerance.

Authors:  Séverine Bézie; Elodie Picarda; Jason Ossart; Laurent Tesson; Claire Usal; Karine Renaudin; Ignacio Anegon; Carole Guillonneau
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.